GLP-1 Drugs Gain Support for Weight Loss: A Public Health Perspective
Medical bodies and experts are increasingly backing GLP-1 drugs for weight loss, especially for those with obesity and related conditions.
Photo by Sweet Life
Quick Revision
GLP-1 drugs are increasingly backed for weight loss
Originally developed for Type 2 diabetes
Obesity is recognized as a chronic disease
Drugs help with weight loss and reduce risks of associated conditions like heart disease and stroke
Accessibility and cost are key concerns in India
Key Numbers
Visual Insights
India's Health Landscape: Context for GLP-1 Drugs
This dashboard highlights key statistics related to the prevalence of obesity and diabetes in India, alongside public health expenditure, providing essential context for the growing support and implications of GLP-1 drugs for weight loss.
- Adult Overweight/Obesity (Women)
- ~24%
- Adult Overweight/Obesity (Men)
- ~23%
- Diabetes Prevalence (Adults)
- ~11.4%
- Public Health Expenditure (Current)
- ~1.5% of GDP
As per NFHS-5 (2019-21), indicating a significant and rising burden of weight-related issues among women, a primary target group for GLP-1 drugs.
NFHS-5 data shows a similar trend among men, underscoring the widespread nature of obesity as a public health challenge.
Latest ICMR-INDIAB study (2023) reveals a high and increasing prevalence of diabetes, for which GLP-1 drugs were originally developed and are highly effective.
India's current public health spending is significantly below the NHP 2017 target of 2.5% of GDP, posing challenges for drug accessibility and comprehensive NCD management.
Exam Angles
Public Health and NCD burden in India (GS-II)
Healthcare access, affordability, and equity (GS-II)
Drug regulation and pharmaceutical policy (GS-II, GS-III)
Science & Technology: Biotechnology, pharmacology, drug development (GS-III)
Ethical considerations in medical treatment and drug prescription (GS-IV)
View Detailed Summary
Summary
A growing consensus among medical professionals and health organizations is emerging in support of using GLP-1 (Glucagon-Like Peptide-1) drugs for weight loss, particularly for individuals struggling with obesity and related health issues like diabetes. These drugs, originally developed for Type 2 diabetes, have shown significant efficacy in promoting weight loss.
The article discusses how various medical bodies are now endorsing their use, recognizing obesity as a chronic disease requiring comprehensive treatment. This shift has major implications for public health, drug accessibility, and the management of non-communicable diseases in India, potentially leading to new guidelines and increased demand for these medications.
Background
Latest Developments
Practice Questions (MCQs)
1. Consider the following statements regarding GLP-1 (Glucagon-Like Peptide-1) drugs: 1. They were originally developed for the treatment of Type 2 Diabetes Mellitus. 2. Their mechanism of action primarily involves increasing glucagon secretion and slowing gastric emptying. 3. Obesity is now widely recognized as a chronic disease, distinct from being merely a lifestyle choice. Which of the statements given above is/are correct?
- A.1 and 2 only
- B.1 and 3 only
- C.2 and 3 only
- D.1, 2 and 3
Show Answer
Answer: B
Statement 1 is correct. GLP-1 drugs were indeed first developed for Type 2 Diabetes. Statement 2 is incorrect. GLP-1 receptor agonists primarily work by increasing insulin secretion (glucose-dependent), suppressing glucagon secretion, slowing gastric emptying, and promoting satiety, leading to weight loss. They do not increase glucagon secretion. Statement 3 is correct. There is a growing medical consensus to recognize obesity as a chronic disease requiring comprehensive medical management.
2. In the context of managing Non-Communicable Diseases (NCDs) in India, which of the following statements is/are correct? 1. The National Programme for Prevention & Control of Cancer, Diabetes, Cardiovascular Diseases & Stroke (NPCDCS) is a key initiative under the National Health Mission. 2. Ayushman Bharat Pradhan Mantri Jan Arogya Yojana (PMJAY) primarily focuses on providing financial protection for tertiary care hospitalizations for NCDs. 3. The World Health Organization (WHO) recommends a 'whole-of-government' and 'whole-of-society' approach for NCD prevention and control globally. Select the correct answer using the code given below:
- A.1 only
- B.2 and 3 only
- C.1 and 3 only
- D.1, 2 and 3
Show Answer
Answer: C
Statement 1 is correct. NPCDCS is a major program under the National Health Mission (NHM) aimed at addressing NCDs. Statement 2 is incorrect. While PMJAY does cover tertiary care, its scope is broader, covering secondary and tertiary care hospitalizations for a wide range of diseases, not *primarily* NCDs, and it's part of a larger Ayushman Bharat initiative that also includes Health and Wellness Centres for primary care. Statement 3 is correct. WHO strongly advocates for a multi-sectoral, 'whole-of-government' and 'whole-of-society' approach to tackle the complex challenges of NCDs.
3. Match List-I with List-II: List-I (Regulatory Body/Initiative) List-II (Primary Function/Focus) A. CDSCO 1. Price control of scheduled essential medicines B. NPPA 2. Approval of new drugs and clinical trials C. National Health Mission 3. Strengthening public health infrastructure and human resources D. Ayushman Bharat Health & Wellness Centres 4. Comprehensive primary healthcare services Select the correct match using the code given below:
- A.A-2, B-1, C-3, D-4
- B.A-1, B-2, C-3, D-4
- C.A-2, B-1, C-4, D-3
- D.A-1, B-2, C-4, D-3
Show Answer
Answer: A
A. CDSCO (Central Drugs Standard Control Organization) is responsible for approval of new drugs, clinical trials, and maintaining drug quality standards. B. NPPA (National Pharmaceutical Pricing Authority) is responsible for controlling the prices of scheduled essential medicines. C. National Health Mission (NHM) aims at strengthening public health infrastructure, human resources, and improving health outcomes across various programs. D. Ayushman Bharat Health & Wellness Centres (AB-HWCs) are designed to provide comprehensive primary healthcare services closer to the community.